Transcript of Interview on Ampyra Research, MS Walking Ability and Long-Term Use
Multiple Sclerosis News Today interviewed Dr. Linard Filli, an MS researcher at the University Hospital Zurich involved in clinical studies of prolonged release Ampyra (dalfampridine), on walking ability in MS patients, and Dr. Andrew Blight, chief scientific officer at Acorda Therapeutics, the treatment’s developer. Here is a full transcript of that interview. An…